Both in Pharmaceuticals
Emergent Biosolutions vs ARS Pharmaceuticals
Over the past year EBS returned −40.4% and SPRY returned −64.6%; their daily moves had a correlation of 0.22.
EBS −40.4% SPRY −64.6%Growth of $1, one year, split-adjusted
| Metric | EBS | SPRY |
|---|---|---|
| Price | $6.25 | $3.05 |
| Market cap | $320.5M | $303.3M |
| Today | −2.95% | 0.00% |
| 1 month | −13.7% | −28.9% |
| 6 months | −30.9% | −66.2% |
| Year to date | −49.4% | −73.8% |
| 1 year | −49.9% | −66.0% |
| Revenue growth (YoY) | +66.3% | +114.2% |
| Gross margin | 58.6% | 61.8% |
| Net margin | −76.9% | −185.2% |
| P/E (TTM) | — | — |
| Price / sales | 0.4× | 2.6× |
| Net cash | -$442.1M | -$27.8M |
| Dividend yield | — | — |
| Volatility (60d) | 63.6% | 70.0% |
| Short % of float | 19.3% | 40.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).